Cerilliant Corp, Round Rock, Texas, offers five recently released stable-labeled internal standards of the antifungal agents fluconazole, itraconazole, ketoconazole, posaconazole, and voriconazole at 1.0 mg/mL concentrations.

Antifungal agents offer critically ill or immunocompromised patients multiple treatment options against invasive fungal infections. However, because of their ability to act as a substrate or inhibitor of cytochrome P450 (CYP) metabolic enzymes, antifungal agents can also result in several clinical challenges, including interactions with coadministered drugs, concentration-dependent toxicity, and variations in drug absorption and?metabolism.1,2 Therapeutic drug monitoring (TDM) by liquid chromatography–mass spectrometry (LC-MS) is used to avoid such adverse clinical outcomes and to ensure the effectiveness of the drug regimen.2,3

Cerilliant’s solution certified reference materials offer a full selection of internal standards for quantitation of the most common antifungal drugs in serum or plasma by mass spectrometry-based analytical methods. The deuterium or carbon-13 substitutions of each internal standard conserve a minimum [M+3] separation from the unlabeled drug in the major ion fragments used in LC-MS/MS antifungal TDM applications and metabolism studies. The reference materials are suitable for use in clinical and diagnostic testing labs; hospitals; and bioanalytical, pharmacokinetics, and drug metabolism labs.

For more information, visit AACC booth 2429 or Cerilliant.


  1. Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–1458; doi: 10.1086/598327.
  1. Snozek C. Antifungal drug monitoring: why, when, and how to measure serum concentrations. Communiqué. [Online briefing.] Mayo Medical Laboratories, 2010. Available at: www.mayomedicallaboratories.com/articles/communique/2010/11.html. Accessed July 10, 2015.
  1. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis. 2000;30(4):653–657; doi: 10.1086/313748.